Levofloxacin

C difficile risk
High
Oral Bioavailability
Excellent

Dosing

  • PNA, Pyelo, IA: 750 mg q24h IV/PO

  • Bronchitis, Prostatitis: 500 mg q24h IV/PO

  • Cystitis: 250 mg q24h IV/PO

CrCl 0 - 20CrCl 20 - 50CrCl > 50- PNA, Pyelo, IA: 750 mg LD, then 500 mg q48h IV/PO

  • Bronchitis, Prostatitis: 500 mg LD, then 250 mg q48h IV/PO

  • Cystitis: 250 mg q48h IV/PO- PNA, Pyelo, IA: 750 mg q48 Iv/PO

  • Bronchitis, Prostatitis: 500 mg LD, then 250 mg q24h IV/PO

  • Cystitis: 250 mg q24h IV/POUsual dosing

500-750 mg LD, then 250 mg - 500 mg q48h IV/PO

500-750 mg LD, 250 - 750 mg q24h IV/PO

General Information

  • Respiratory infections (CAP, AECOPD) for which there are no reasonable alternatives due to susceptibilities and/or life-threatening PCN allergy

Monitor QTc in patients with increased risk

  • GI upset

  • Black Box: Tendinopathy and rupture. Potentially permanent and disabling damage to tendons, muscles, joints, and nervous system including peripheral neuropathies.

  • C difficile infection

  • CNS toxicity including fatigue, confusion, memory impairment, delirium, psychosis

  • Cardiac: QTc prolongation and risk for aortic aneurysm and dissection

  • Severe blood glucose disturbances, including hypoglycemic coma

  • Weakness exacerbation in myasthenia gravis

Warfarin - Increased INR Divalent & trivalent cations including Al, Ca, Fe, Mg (antacids, dairy products, iron supplements, some enteral feeds) - Decreased absorption Oral antidiabetic agents – increased risk of hyper and hypoglycemia, including hypoglycemic coma QTc prolongation - Increased risk with other agents that prolong QTc

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 7 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.